Self-injecting testosterone into your lats: safer or riskier?

What's this video probably claiming?

Based on the caption and hashtags, this creator is walking viewers through self-administered intramuscular (IM) injections into the latissimus dorsi or surrounding paraspinal musculature, framing it as a larger and safer injection site compared to the deltoid. The technique described, quick insertion, slow plunger depression, semi-fast withdrawal, follows a rough approximation of standard IM protocol. The hashtags confirm a TRT and performance-enhancement audience. The cut-off caption suggests the substance was likely a vitamin B12 or testosterone ester solution, common in self-managed TRT communities. The implicit claim is that the lateral back is a legitimate, low-risk IM injection site that holds more volume than the delt, and that laypeople can safely perform it with minimal guidance. That framing deserves serious scrutiny.

What does the science actually show?

The evidence base for self-administered IM injection sites is actually pretty well-defined. Ventrogluteal, dorsogluteal, vastus lateralis, and deltoid are the four sites with robust clinical documentation. The ventrogluteal site, in particular, has been consistently supported as the lowest-risk option for IM injections, with Cocoman and Murray (2008, Journal of Advanced Nursing) and Wynaden et al. (2006, Contemporary Nurse) both citing lower rates of nerve injury and hematoma compared to dorsogluteal injection. Volume capacity varies by site: deltoid handles roughly 1-2 mL, vastus lateralis up to 5 mL in adults, and ventrogluteal up to 4 mL. Injecting into paraspinal or deep back musculature is not a recognized clinical IM site in any major pharmacopeial or nursing guideline. The proximity to the spinal cord, nerve roots, and large vascular structures makes improvised back injections a genuinely different risk category.

Where does the social media noise diverge from clinical reality?

Gym and TRT communities on TikTok have popularized injection sites that simply do not appear in clinical literature, including lats, traps, and pecs. The reasoning usually involves muscle volume, aesthetics (avoiding delt bruising), or injection fatigue from rotating standard sites. This logic sounds plausible but collapses under anatomical scrutiny. The latissimus dorsi is a broad, flat muscle overlying the thoracic and lumbar spine. Injecting into this region risks hitting the serratus anterior, intercostal nerves, or in poorly executed attempts, approaching the pleural space. There are documented case reports of pneumothorax from improper back injections, though these are rare. A 2021 review by Nicholson et al. in Drugs and Aging noted that injection site errors, including non-standard locations, accounted for a meaningful proportion of preventable injection-related adverse events. Social media technique videos frequently omit aspiration debates, sterility verification, and anatomical landmarks entirely.

What should you actually know?

If you are on a medically supervised TRT protocol, your prescribing clinician should be guiding your injection site rotation, not a TikTok caption. Ventrogluteal injection is the most evidence-backed self-injection site for larger volumes, and vastus lateralis is a well-tolerated alternative. Deltoid is appropriate for volumes at or below 2 mL. No peer-reviewed pharmacology or nursing guideline endorses the lateral back as a standard IM injection site. Beyond site selection, injection technique matters significantly. Skin-to-muscle depth varies by body composition, and using the wrong needle length increases the risk of subcutaneous rather than true IM delivery, which affects testosterone absorption rates. Testosterone enanthate and cypionate are approved for IM administration only. Subcutaneous delivery of these esters is practiced off-label in some clinical settings but is not a standard approval. If you are experiencing injection site fatigue or complications, that conversation belongs with your prescribing provider, not a comment section.